Work

Sintilimab plus oxaliplatin and capecitabine versus sintilimab plus albumin-bound paclitaxel and capecitabine for advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma patients: A prospective, randomized, open-label, investigator-initiated phase 2 trial.

Year: 2025

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e16042

Authors: Kai Chen, Wei Li, Caihua Xu, Qing Guo, Dapeng Li, Lian Lian, Xiumin Zhou, Yulan GU, Wei Fu, Weiming Duan, Rong Wang, Yonghua Zhang

Institutions: First Affiliated Hospital of Soochow University, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Nanjing Medical University, Nantong University, Changshu No. 2 People's Hospital, Changshu No.1 People's Hospital

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410810032

FWCI:

Cites:

Cited by:

Related to: 10